Ocular Therapeutix (OCUL) EBIT Margin (2014 - 2026)
Ocular Therapeutix's quarterly EBIT Margin came in at 865.46% in Q1 2026, down 26799.0% year-on-year from N/an in Q1 2025, and down 64.38% quarter-over-quarter from 526.49% in Q4 2025.
Ocular Therapeutix has reported EBIT Margin for 13 years, with the latest figure at 865.46% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 26799.0% year-over-year to 865.46%; the trailing twelve-month figure through Mar 2026 stood at 575.42% (down 23327.0% YoY), and the FY2025 full-year result was 519.75%, down 25018.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 865.46%, down from 526.49% in the prior quarter.
- The five-year high for EBIT Margin was 127.41% in Q3 2023, with the low at 865.46% in Q1 2026.
- Average EBIT Margin over 5 years is 307.05%, with a median of 214.0% recorded in 2024.
- Year-over-year, EBIT Margin soared 14028 bps in 2022 and sank 38346 bps in 2025.
- Tracing OCUL's EBIT Margin over 5 years: stood at 137.56% in 2022, then increased by 2 bps to 135.46% in 2023, then slumped by 119 bps to 296.08% in 2024, then slumped by 78 bps to 526.49% in 2025, then slumped by 64 bps to 865.46% in 2026.
- The last three EBIT Margin figures came in at 865.46% (Q1 2026), 526.49% (Q4 2025), and 472.35% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | -865.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -865.46% |
| Dec 31, 2025 | -526.49% |
| Sep 30, 2025 | -472.35% |
| Jun 30, 2025 | -502.57% |
| Mar 31, 2025 | -597.47% |
| Dec 31, 2024 | -296.08% |
| Sep 30, 2024 | -298.20% |
| Jun 30, 2024 | -265.13% |
| Mar 31, 2024 | -214.00% |
| Dec 31, 2023 | -135.46% |
| Sep 30, 2023 | -127.41% |
| Jun 30, 2023 | -135.45% |
| Mar 31, 2023 | -168.60% |
| Dec 31, 2022 | -137.56% |
| Sep 30, 2022 | -180.06% |
| Jun 30, 2022 | -162.37% |
| Mar 31, 2022 | -135.23% |
| Dec 31, 2021 | -146.64% |
| Sep 30, 2021 | -160.69% |
| Jun 30, 2021 | -172.65% |
| Mar 31, 2021 | -275.51% |
| Dec 31, 2020 | -195.17% |
| Sep 30, 2020 | -238.36% |
| Jun 30, 2020 | -1,139.83% |
| Mar 31, 2020 | -636.80% |
| Dec 31, 2019 | -948.63% |
| Sep 30, 2019 | -2,791.80% |
| Jun 30, 2019 | -3,322.92% |
| Mar 31, 2019 | -3,995.53% |
| Dec 31, 2018 | -3,429.17% |
| Sep 30, 2018 | -2,975.10% |
| Jun 30, 2018 | -2,093.21% |
| Mar 31, 2018 | -3,957.35% |
| Dec 31, 2017 | -2,611.09% |
| Sep 30, 2017 | -2,905.54% |
| Jun 30, 2017 | -4,186.99% |
| Mar 31, 2017 | -3,299.37% |
| Dec 31, 2016 | -2,440.70% |
| Sep 30, 2016 | -1,936.69% |
| Jun 30, 2016 | -2,518.59% |
| Mar 31, 2016 | -2,526.20% |
| Dec 31, 2015 | -2,607.87% |
| Sep 30, 2015 | -27,253.66% |
| Jun 30, 2015 | -2,099.13% |
| Mar 31, 2015 | -2,988.66% |
| Dec 31, 2014 | -1,494.46% |
| Sep 30, 2014 | -4,738.46% |
| Jun 30, 2014 | -6,129.90% |
| Mar 31, 2014 | -25,277.78% |